Servier, armed with Shire cancer drugs, builds out vision for U.S. future

France’s second-largest drugmaker, Servier, is in 150 countries. But it hasn’t had a presence in the U.S.—until now. Since buying up merger-bound Shire’s oncology business for $2.4 billion, the company has been working to define itself in pharma’s largest market.